Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

5.880 -7.790 (-56.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
News headline image
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ ↗
The Food and Drug Administration said in a letter to the company that it is unable to approve its EBVALLO application in present form, citing inadequate evidence of effectiveness for accelerated... 
Via Stocktwits
Gapping stocks in Monday's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
Via Benzinga
News headline image
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Pricing of $16 Million Offering
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs ↗
FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval. 
Via Benzinga
News headline image
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates ↗
 
Via Benzinga
News headline image
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip ↗
CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns. 
Via Stocktwits
News headline image
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.